» Articles » PMID: 28157158

Epigenetic Alterations in Parathyroid Cancers

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Feb 4
PMID 28157158
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Parathyroid cancers (PCas) are rare malignancies representing approximately 0.005% of all cancers. PCas are a rare cause of primary hyperparathyroidism, which is the third most common endocrine disease, mainly related to parathyroid benign tumors. About 90% of PCas are hormonally active hypersecreting parathormone (PTH); consequently patients present with complications of severe hypercalcemia. Pre-operative diagnosis is often difficult due to clinical features shared with benign parathyroid lesions. Surgery provides the current best chance of cure, though persistent or recurrent disease occurs in about 50% of patients with PCas. Somatic inactivating mutations of CDC73/HRPT2 gene, encoding parafibromin, are the most frequent genetic anomalies occurring in PCas. Recently, the aberrant DNA methylation signature and microRNA expression profile have been identified in PCas, providing evidence that parathyroid malignancies are distinct entities from parathyroid benign lesions, showing an epigenetic signature resembling some embryonic aspects. The present paper reviews data about epigenetic alterations in PCas, up to now limited to DNA methylation, chromatin regulators and microRNA profile.

Citing Articles

Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.

Popow M, Kaszczewska M, Goralska M, Kaszczewski P, Skwarek-Szewczyk A, Chudzinski W Am J Case Rep. 2022; 23:e936135.

PMID: 36271606 PMC: 9597261. DOI: 10.12659/AJCR.936135.


miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2.

Kooblall K, Stokes V, Shariq O, English K, Stevenson M, Broxholme J Endocr Relat Cancer. 2022; 29(10):557-568.

PMID: 35900839 PMC: 9422251. DOI: 10.1530/ERC-22-0045.


Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Uljanovs R, Sinkarevs S, Strumfs B, Vidusa L, Merkurjeva K, Strumfa I Int J Mol Sci. 2022; 23(13).

PMID: 35805976 PMC: 9266566. DOI: 10.3390/ijms23136981.


Histone Modification on Parathyroid Tumors: A Review of Epigenetics.

de Freitas L, Castilho R, Squarize C Int J Mol Sci. 2022; 23(10).

PMID: 35628190 PMC: 9140881. DOI: 10.3390/ijms23105378.


Parathyroid Carcinoma: a Review.

Sawhney S, Vaish R, Jain S, Mittal N, Ankathi S, Thiagarajan S Indian J Surg Oncol. 2022; 13(1):133-142.

PMID: 35462650 PMC: 8986943. DOI: 10.1007/s13193-021-01343-3.


References
1.
Cryns V, Rubio M, Thor A, Louis D, Arnold A . p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 1994; 78(6):1320-4. DOI: 10.1210/jcem.78.6.8200932. View

2.
Christakis I, Bussaidy N, Clarke C, Kwatampora L, Warneke C, Silva A . Differentiating Atypical Parathyroid Neoplasm from Parathyroid Cancer. Ann Surg Oncol. 2016; 23(9):2889-97. DOI: 10.1245/s10434-016-5248-6. View

3.
Haven C, Howell V, Eilers P, Dunne R, Takahashi M, van Puijenbroek M . Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004; 64(20):7405-11. DOI: 10.1158/0008-5472.CAN-04-2063. View

4.
Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A . Integrative analysis of 111 reference human epigenomes. Nature. 2015; 518(7539):317-30. PMC: 4530010. DOI: 10.1038/nature14248. View

5.
Mosimann C, Hausmann G, Basler K . Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell. 2006; 125(2):327-41. DOI: 10.1016/j.cell.2006.01.053. View